Jounce Therapeutics to Participate in William Blair’s Biotech Focus Conference

Rhea-AI Summary

Jounce Therapeutics (NASDAQ: JNCE) announced that its Chief Scientific Officer, Dmitri Wiederschain, will participate in a panel at the William Blair’s Biotech Focus Conference on July 14, 2021, at 4:20 PM ET. The event will be held virtually, and a webcast of the discussion will be accessible via Jounce's website, with a replay available for 30 days post-event. Jounce specializes in developing cancer immunotherapies and has multiple ongoing clinical trials, including its key programs JTX-8064 and vopratelimab.

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Dmitri Wiederschain, Ph.D., Chief Scientific Officer will participate in a panel discussion at the William Blair’s Biotech Focus Conference taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.

A webcast of the panel will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a monotherapy and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce obtained IND clearance for and exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Investor and Media Contacts:

Mark Yore
Jounce Therapeutics, Inc.
+1-857-200-1255
myore@jouncetx.com

Julie Seidel
Stern Investor Relations
+1-212-362-1200
Julie.Seidel@sternir.com

FAQ

What is the date and time of Jounce Therapeutics' panel discussion at the William Blair’s Biotech Focus Conference?

The panel discussion will take place on July 14, 2021, at 4:20 PM ET.

Who is participating in the panel discussion at the William Blair’s Biotech Focus Conference?

Dmitri Wiederschain, Ph.D., Chief Scientific Officer of Jounce Therapeutics, will participate.

How can I access the webcast of the Jounce Therapeutics panel discussion?

You can access the webcast by visiting the 'Events and Presentations' section of Jounce's website.

What are the main programs being developed by Jounce Therapeutics?

Jounce's main programs include JTX-8064, a receptor antagonist, and vopratelimab, a monoclonal antibody targeting ICOS.

What is the significance of Jounce's JTX-8064 program?

JTX-8064 is designed to reprogram immune-suppressive tumor-associated macrophages to an anti-tumor state and is undergoing clinical trials.